Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals (ALNY) is a biotechnology company that develops RNA interference (RNAi) therapeutics to silence disease-causing genes. Investors should know it has moved from research-stage to a commercial entity, with multiple approved medicines for rare genetic disorders — including treatments for hereditary ATTR amyloidosis, acute hepatic porphyria and primary hyperoxaluria — and a broad pipeline built on its GalNAc delivery platform. The business is growth-oriented: revenues depend on uptake of marketed drugs, pricing and successful launches of late-stage candidates. Key risks include trial outcomes, regulatory decisions, pricing pressures, manufacturing scale-up and competition from other modalities. With a market capitalisation near $62.13 billion, Alnylam may appeal to investors seeking exposure to innovative therapeutics, but it suits those comfortable with biotech volatility. This is general information for educational purposes only and not personalised investment advice; values can fall as well as rise.
Why It's Moving
Alnylam Shares Surge on Profitability Milestone and Robust 2026 Growth Outlook
- Quarterly results delivered net income of $314 million on $3.71 billion in revenue, marking a pivotal shift to profitability that reassures markets of Alnylam's maturing business model.
- 2026 outlook projects net product revenues of $4.9 billion to $5.3 billion, highlighting AMVUTTRA's rapid expansion and potential to drive double-digit growth despite a modest near-term revenue dip.
- Freedom Capital Markets upgraded to Buy with analysts eyeing strong upside, reflecting confidence in the RNAi pipeline and operational scaling even as insiders trim holdings.
Alnylam Shares Surge on Profitability Milestone and Robust 2026 Growth Outlook
- Quarterly results delivered net income of $314 million on $3.71 billion in revenue, marking a pivotal shift to profitability that reassures markets of Alnylam's maturing business model.
- 2026 outlook projects net product revenues of $4.9 billion to $5.3 billion, highlighting AMVUTTRA's rapid expansion and potential to drive double-digit growth despite a modest near-term revenue dip.
- Freedom Capital Markets upgraded to Buy with analysts eyeing strong upside, reflecting confidence in the RNAi pipeline and operational scaling even as insiders trim holdings.
When is the next earnings date for Alnylam Pharmaceuticals, Inc. (ALNY)?
Alnylam Pharmaceuticals is scheduled to report its next earnings on April 29, 2026, covering Q1 2026 results. The company has previously reported Q1 earnings in late February, though this year's report will come slightly later in April. Investors should note that the exact timing may be subject to confirmation by the company, as final dates are occasionally adjusted. This earnings release will provide updated financial performance and guidance for the pharmaceutical firm.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Alnylam Pharmaceuticals' stock with a target price of $495.04, indicating growth potential.
Financial Health
Alnylam Pharmaceuticals is generating strong profits and revenue, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ALNY
Pioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: July 21, 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketSafer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published: July 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
RNAi platform potential
Alnylam’s GalNAc delivery platform enables targeted gene silencing across liver-related diseases, which could drive long-term growth, though clinical and commercial execution matters.
Clinical catalysts ahead
Late-stage trial readouts and new approvals can be material share-price catalysts; remember that trial or regulatory setbacks can also move the stock substantially.
Rare-disease reach
Market opportunity centres on rare, high‑need conditions where few therapies exist, but pricing, access and competition will influence commercial outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
